In the preceding three months, 9 analysts have released ratings for Ventas VTR, presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 0 | 7 | 2 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 0 | 2 | 0 | 0 | 0 |
2M Ago | 0 | 2 | 0 | 0 | 0 |
3M Ago | 0 | 3 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $64.78, a high estimate of $71.00, and a low estimate of $56.00. This current average reflects an increase of 11.48% from the previous average price target of $58.11.
Decoding Analyst Ratings: A Detailed Look
In examining recent analyst actions, we gain insights into how financial experts perceive Ventas. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Nicholas Yulico | Scotiabank | Raises | Sector Perform | $65.00 | $59.00 |
John Kilichowski | Wells Fargo | Raises | Overweight | $71.00 | $61.00 |
Steve Sakwa | Evercore ISI Group | Raises | Outperform | $70.00 | $64.00 |
Richard Anderson | Wedbush | Raises | Outperform | $71.00 | $64.00 |
Steve Sakwa | Evercore ISI Group | Raises | Outperform | $64.00 | $61.00 |
Michael Carroll | RBC Capital | Raises | Outperform | $63.00 | $52.00 |
Nicholas Yulico | Scotiabank | Raises | Sector Perform | $59.00 | $55.00 |
Richard Anderson | Wedbush | Raises | Outperform | $64.00 | $54.00 |
Steve Sakwa | Evercore ISI Group | Raises | Outperform | $56.00 | $53.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ventas. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Ventas compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Ventas's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
For valuable insights into Ventas's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Ventas analyst ratings.
Discovering Ventas: A Closer Look
Ventas owns a diversified healthcare portfolio of over 1,300 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
Unraveling the Financial Story of Ventas
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Ventas's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.55% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ventas's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.2%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Ventas's ROA stands out, surpassing industry averages. With an impressive ROA of 0.08%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Ventas's debt-to-equity ratio is below the industry average. With a ratio of 1.39, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.